anti-PRAME (EPR20330) Rabbit Monoclonal Primary Antibody
H&E is the primary tool for diagnostic evaluation of potential melanocytic lesions. However, not all melanomas are easily diagnosed using H&E alone.
PRAME expression in formalin-fixed paraffin-embedded tissue is detected by immunohistochemistry and frequently demonstrates a diffuse nuclear immunostaining pattern in in situ and invasive melanoma. In contrast, the majority of benign melanocytic nevi lack nuclear PRAME staining.1
Diffuse PRAME expression in a melanoma can improve our confidence and diagnostic accuracy, and lead to more informed clinical decisions, and improved patient outcomes.
The PRAME (EPR20330) Antibody is the latest addition to Roche’s robust dermatology portfolio with more than 50 dermatology biomarkers designed to meet a broad range of diagnostic needs.
Fully validated on all BenchMark IHC/ISH systems and supported by Roche, anti-PRAME (EPR20330) antibody provides consistent, high quality PRAMEÂ staining results with the flexibility to use OptiView DAB IHC Detection, ultraView Unversal DAB Detection, or ultraView Universal Alkaline Phosphatase Red Detection Kits.
References
- Lezcano, C. et al. PRAME immunohistochemistry as an ancillary test for the assessment of melanocytic lesions. Surg Pathol Clin 2021 Jun;14(2):165-175.
Use left and right arrow keys to scroll between the tabs
